$AMBQ

Hanson Scott McLean sold $451K of AMBQ

Hanson Scott McLean (Chief Technology Officer) sold 7,000 shares of Ambiq Micro, Inc. (AMBQ) at an average of $64.38 ($63.26–$65.30, $0.45M total) across 3 trades on 2026-08-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hanson Scott McLean
Published Aug 18, 2026, 8:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 9:23 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AMBQ
Neutral
high confidence
Mentioned
$AMBQ
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMBQNeutralLow
01

Why it matters

The disclosed transaction is an open-market sale executed under a pre-arranged Rule 10b5-1 plan, which typically reduces the informational content versus discretionary selling.

02

Market read

Traders may note the insider sale for sentiment, but there is no new fundamental information in the text.

03

What to watch

The article does not state whether other insiders or institutions are buying/selling, nor does it provide context on total insider ownership changes beyond the post-transaction share count.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-18, covering sales dated 2026-08-14

Background

The article is an SEC Form 4 disclosure of an insider sale by Ambiq Micro CTO Hanson Scott McLean.

Company-level read

Ticker impact

$AMBQNeutralHigh confidence
Context

Ambiq Micro CTO Hanson Scott McLean sold about 7,000 shares in open-market trades totaling $450,638.94 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale; any impact is likely short-lived.

Evidence & confidence

The filing is an SEC Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and the article contains no new operational or financial catalyst.

Market effects

No direct sector read-through; this is company-specific insider liquidity activity.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, the market may overreact; traders could treat it as non-informational and focus on other catalysts.

Key entities

  • Ambiq Micro, Inc.

    Company whose insider transaction is disclosed in the Form 4.

  • Hanson Scott McLean

    Chief Technology Officer and director who sold shares.

  • Rule 10b5-1 plan

    Pre-arranged plan that governs the timing of insider trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Ambiq Micro, Inc. Q2 2026 Earnings Call Summary

Ambiq Micro reported Q2 2026 results and said revenue rose 90% year over year, driven by stronger Edge AI demand and growth across Apollo II and Apollo IV, with Apollo V more than doubling on a new large customer ramp. Management projected Q3 net sales up ~100% YoY and 2026 revenue about $135M, despite supply constraints limiting shipments. Gross margin expected to improve modestly in 2026.

Med

Ambiq Micro Q2 net loss narrows to US$7.1 million as edge AI sales surge

Ambiq Micro reported Q2 net loss of $7.1 million, or $0.32 per share, narrowing from $8.5 million a year earlier, as revenue rose 89.7% on stronger demand for ultra-low power edge AI chips. Q2 gross profit more than doubled to $15.3 million and gross margin rose to 45%. H1 net loss was $17.3 million. Cash was $366.8 million after a June follow-on raising $167.9 million net proceeds.

$AMBQHighAI 9/10

Ambiq (AMBQ) Q2 2026 Earnings Call Transcript

Ambiq Micro (AMBQ) reported Q2 2026 net sales of $33.9 million, up 89.7% year over year, citing accelerating edge AI demand. Non-GAAP gross margin was 47.2%. Full-year net sales guidance is about $135 million, with Q3 revenue outlook of $36 million to $37 million. Management cited supply constraints limiting order fulfillment and said cash was $366.8 million as of June 30, 2026.